These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 6513680

  • 21. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin.
    Deep G, Singh RP, Agarwal C, Kroll DJ, Agarwal R.
    Oncogene; 2006 Feb 16; 25(7):1053-69. PubMed ID: 16205633
    [Abstract] [Full Text] [Related]

  • 22. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels.
    Singh RP, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R.
    Cancer Res; 2002 Jun 01; 62(11):3063-9. PubMed ID: 12036915
    [Abstract] [Full Text] [Related]

  • 23. [Studies of the metabolism and excretion of silybin in the rat].
    Bülles H, Bülles J, Krumbiegel G, Mennicke WH, Nitz D.
    Arzneimittelforschung; 1975 Jun 01; 25(6):902-5. PubMed ID: 1174327
    [Abstract] [Full Text] [Related]

  • 24. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells.
    Agarwal C, Singh RP, Dhanalakshmi S, Tyagi AK, Tecklenburg M, Sclafani RA, Agarwal R.
    Oncogene; 2003 Nov 13; 22(51):8271-82. PubMed ID: 14614451
    [Abstract] [Full Text] [Related]

  • 25. PK/PD modelling of high-dose diltiazem--absorption-rate dependency of the hysteresis loop.
    Luckow V, Della Paschoa O.
    Int J Clin Pharmacol Ther; 1997 Oct 13; 35(10):418-25. PubMed ID: 9352390
    [Abstract] [Full Text] [Related]

  • 26. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1994 Dec 13; 435():1-288. PubMed ID: 12595928
    [Abstract] [Full Text] [Related]

  • 27. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB, Dowell JA, Pratt RD.
    Clin Ther; 2007 Jul 13; 29(7):1368-80. PubMed ID: 17825688
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Therapeutic value of orally administered silibinin in renal cell carcinoma: manipulation of insulin-like growth factor binding protein-3 levels.
    Cheung CW, Taylor PJ, Kirkpatrick CM, Vesey DA, Gobe GC, Winterford C, Nicol DL, Johnson DW.
    BJU Int; 2007 Aug 13; 100(2):438-44. PubMed ID: 17617146
    [Abstract] [Full Text] [Related]

  • 31. Enhancement of mammary carcinogenesis in two rodent models by silymarin dietary supplements.
    Malewicz B, Wang Z, Jiang C, Guo J, Cleary MP, Grande JP, Lü J.
    Carcinogenesis; 2006 Sep 13; 27(9):1739-47. PubMed ID: 16597642
    [Abstract] [Full Text] [Related]

  • 32. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats.
    Boigk G, Stroedter L, Herbst H, Waldschmidt J, Riecken EO, Schuppan D.
    Hepatology; 1997 Sep 13; 26(3):643-9. PubMed ID: 9303494
    [Abstract] [Full Text] [Related]

  • 33. Comparative pharmacokinetics of silipide and silymarin in rats.
    Morazzoni P, Montalbetti A, Malandrino S, Pifferi G.
    Eur J Drug Metab Pharmacokinet; 1993 Sep 13; 18(3):289-97. PubMed ID: 8149949
    [Abstract] [Full Text] [Related]

  • 34. Plasma lipoproteins in transport of silibinin, an antioxidant flavonolignan from Silybum marianum.
    Svagera Z, Skottová N, Vána P, Vecera R, Urbánek K, Belejová M, Kosina P, Simánek V.
    Phytother Res; 2003 May 13; 17(5):524-30. PubMed ID: 12748991
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [The solubility and bioequivalence of silymarin preparations].
    Schulz HU, Schürer M, Krumbiegel G, Wächter W, Weyhenmeyer R, Seidel G.
    Arzneimittelforschung; 1995 Jan 13; 45(1):61-4. PubMed ID: 7893272
    [Abstract] [Full Text] [Related]

  • 39. Serum and urinary levels of fentiazac after a single oral and epicutaneous administration in human subjects.
    Quattrini M, Zanolo G, Mondino A, Giachetti C, Silvestri S.
    Arzneimittelforschung; 1981 Jan 13; 31(6):1046-8. PubMed ID: 7196238
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.